Moderna jumps into pivotal pack with promising RSV data as big rivals face off in megablockbuster race
There’s a foot race developing for the lead of a multibillion-dollar vaccine market. And once again, Moderna $MRNA promises to be right in the thick of things as some of the biggest blockbuster players in biopharma hustle toward the finish line.
After the market closed on Tuesday, the big biotech, which has been in the vanguard of the mRNA revolution on Covid vaccines, put out word that it had aced its pivotal trial for a new RSV vaccine dubbed mRNA-1345 among older people above the age of 60. Moderna CEO Stéphane Bancel headlined the news with a clearly statistically significant effect offering 83.7% efficacy in preventing lower respiratory tract disease among people with two or more symptoms of disease.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.